drugset / Trial / NCT06990269
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Timeline
- Start
- 2025-11-10
- Primary completion
- 2030-02-28
- Completion
- 2030-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPI-1007 | Small interfering RNA (siRNA) | — | Subcutaneous |